Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U.
Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Last Update Posted : September 2, See Contacts and Locations. Study Description. The investigators propose to test the use of pramipexole in patients being treated for Opioid Use Disorder to test its ability to reduce symptoms of both Restless Legs Syndrome and protracted opioid withdrawal and thereby promote initiation, engagement, and retention in treatment.
Detailed Description:. MedlinePlus related topics: Restless Legs. Drug Information available for: Pramipexole dihydrochloride Pramipexole. FDA Resources. Pregabalin brought significant relief to the symptoms of RLS and sleep quality.
Conclusion: RLS during opioid withdrawal was an independent illness seen in half of the patients. It appeared to be mediated through mu-receptors, with contributions from other factors.
Pregabalin improved symptoms of RLS and quality of sleep in these patients. Keywords: Mu-receptors; Opioid withdrawal; Pregabalin; Sleep quality. For which steroid supplementation was given. A year-old male with no significant family history and past history of trichotillomania was dependent to opioid DPP and codeine containing cough syrup for last 12 years.
He tried to quit multiple times, also underwent rapid detoxification under anesthesia a year back, but relapsed eventually. They had received clonidine 0.
With these medications rhinorrhea, lacrimation, loose motion, bodyache, anxiety had been resolved, but sleep problem persisted in the form of sleep induction and maintenance problem The dose of BZD was increased in each case nitrazepam up to 30 mg and clonazepam up to 4 mg , but sleep disturbances continued even after 2 weeks. Clinically, this was fulfilling the criteria for RLS.
So a neurology consultation was taken to substantiate the diagnosis. Serum urea, creatinine, ferritin, thyroid function test were conducted along with electroencephalogram. All these investigations came out to be normal. The patients were started on ropinirole 0. Two of them improved with in next 2 days and the third patient required dose escalation to 1. BZDs were tapered off successfully, but ropinirole was continued for next 1 month then was tapered of over 2 weeks uneventfully.
All the patients were young adults dependent to synthetic opioids for a variable period. Two of them had a history of opioid induced seizure. Their RLS like symptoms had persisted beyond 2 weeks when all other symptoms of opioid withdrawal had resolved.
So RLS can be viewed as an independent disorder in these patients. It's response to dopamine agonist rather than formal treatment of withdrawal further substantiates it as a separate disorder. Let's see if there is any common etiopathogenic mechanism to explain the association between the opioid dependence and RLS. As we know dopamine[ 4 ] as evidenced by improvement with Levo-dihydroxy phenyl alanine L-DOPA , circadian symptom pattern, increased symptom with dopamine antagonists and decreased level of D2-receptor in the striatum, fluoro-dihydroxyphenylalanine FDOPA uptake was found reduced in putamen and caudate nucleus and opioid[ 3 ] response to opioid agonist and significant negative correlation between opioid receptor availability and severity of RLS symptoms have being implicated for a long time in the pathogenesis of RLS.
Psychiatry Investigation ;11 2 Published online: April 11, Abstract We report a young man who had received tramadol for pain control and experienced an uncomfortable sensation in both legs immediately after tramadol withdrawal that worsened at rest and at night, and which could be relieved only by moving the legs.
In this paper, we present a case that developed restless legs syndrome RLS following cessation of tramadol intake, which very likely was related to a withdrawal-like symptomatology. He complained of severe left pleuritic pain and dyspnea with large amount of parapneumonic effusion. Thus, he had been treated by chest-tube insertion with antibiotics and an analgesic tramadol at 50 mg t. His symptomatology had largely resolved after 3 weeks of hospital treatment, and so he was discharged to day-clinic treatment.
Following discharge, tramadol was discontinued because his pain had disappeared. However, from the first night after tramadol withdrawal he experienced an uncomfortable sensation in both legs that worsened at rest and at night, and which could be relieved only by moving the legs. The patient did not have any other disease related to secondary RLS. He also had no brain disease, and his only medication was cefixime.
All of his routine laboratory parameters were within normal limits. The patient subsequently attempted withdrawal of the mg tramadol himself, which resulted in the recurrence of his RLS symptoms, prompting him to readminister tramadol. At a follow-up visit after 4 days his tramadol was replaced with ropinirole and clonazepam, which reversed his RLS symptoms.
Ropinirole and clonazepam administration was discontinued after several weeks, and there was no recurrence of his RLS symptoms. The present case had no history of RLS symptoms or insomnia, with his RLS symptoms beginning immediately after the abrupt cessation of tramadol therapy.
Based on the Naranjo probability scale, 11 the present RLS strongly suggests a close relationship to the previous intake of tramadol. In addition, rechallenge with tramadol 50 mg once a day made his RLS symptoms disappear. The physical examination and laboratory findings of our patient revealed no evidence of any of the known forms of secondary RLS or of a comorbid organic disorder.
0コメント